CSL (ASX:CSL) Insider Buys A$99,745.80 in Stock

CSL Limited (ASX:CSL) insider Brian Daniels acquired 3,400 shares of the stock in a transaction dated Tuesday, November 18th. The shares were purchased at an average price of A$29.34 per share, for a total transaction of A$99,745.80.

CSL Price Performance

The firm has a market cap of $77.43 billion, a P/E ratio of 28.02, a price-to-earnings-growth ratio of 1.29 and a beta of 0.32. The company has a debt-to-equity ratio of 64.46, a quick ratio of 1.68 and a current ratio of 1.86.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.